Norwegian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antifungal/neoplasms
Koblingen er lagret på utklippstavlen
Side 1 fra 6124 resultater
Therapeutic targets in cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is related to the following U.S. Applications: U.S. Ser. No. 10/034,650, filed Dec. 20, 2001; U.S. Ser. No. 10/035,832, filed Dec. 26, 2001; U.S. Ser. No. 10/004,113, filed Oct. 23, 2001; U.S. Ser. No. 09/997,722, filed Nov. 30, 2001; U.S.
Therapeutic targets in cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is related to the following U.S. applications: U.S. Ser. No. 10/034,650, filed Dec. 20, 2001; U.S. Ser. No. 10/035,832, filed Dec. 26, 2001; U.S. Ser. No. 10/004,113, filed Oct. 23, 2001; U.S. Ser. No. 09/997,722, filed Nov. 30, 2001; U.S.
Salmonella cancer therapeutics and related therapeutic methods
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
The use of bacteria to treat cancer has been investigated for well over 150 years, and many genera of bacteria, including Clostridium, Bifidus, and Salmonella, have been shown to preferentially accumulate in tumor tissue and cause regression. The efficacy of such standard
Systems and methods for providing dynamic, individualized digital therapeutics for cancer prevention, detection, treatment, and survivorship
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
TECHNICAL FIELD
This document generally relates to computing techniques that can be used to efficiently provide digital therapeutics and precision medicine.
BACKGROUND
Due to the effectiveness of modern cancer treatment, patients are surviving cancer at higher rates and with longer expected
NEAT1 as a prognostic marker and therapeutic target for prostate cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
INCORPORATION BY REFERENCE OF SEQUENCE LISTING
The Sequence Listing in an ASCII text file, named 31008--6063--03--US--Sequence Listing.txt of 44 KB, created on Oct. 13, 2016 , and submitted to the United States Patent and Trademark Office via EFS-Web, is incorporated herein by reference.
FIELD OF
Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
The membrane type (MT)-matrix metalloproteinases (MMPs) constitute a sub-group of membrane-anchored MMPs that are major mediators of pericellular proteolysis and physiological activators of pro-MMP-2. MT-MMPs activate the zymogenic form of MMP-2 (pro-MMP-2 or pro-gelatinase A). MMP-2, in
Method and kit for predicting the therapeutic response of a drug against a malignant tumor
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The present invention relates generally to a method of predicting the therapeutic response of a drug. More specifically, the invention relates to a method of predicting the therapeutic response of a drug directed
towards a malignant tumour in a human patient, and to a diagnostic kit in order to
Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
SEQUENCE LISTING
The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 30, 2012, is named 1379448102.txt and is 31,008 bytes in size.
TECHNICAL FIELD OF THE
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
(a) Field
The subject matter disclosed generally relates to methods of inhibiting cancer tumor growth in a patient in need thereof. More specifically, the subject matter disclosed relates to methods of inhibiting cancer tumor growth in a patient by administering a first treatment
Therapeutic implications of dickkopf affecting cancer stem cell fate
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
This Application claims benefit of U.S. Provisional Patent Application Ser. No. 61/159,123 filed Mar. 11, 2009, the contents of which are incorporated herein by reference.
A. TECHNICAL FIELD
Breast cancer is the most prevalent cancer among women worldwide and current therapies still fall short of
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
1. Field of the Invention
The field of this invention is identifying, treating and monitoring patients having breast cancer or patients at risk of getting breast cancer.
2. Description of the Background Art
Estrogen activity has an established relationship to breast
Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage entry under 35 U.S.C. .sctn.371 of PCT International Patent Application No. PCT/EP2012/67758, filed Sep. 12, 2012, which claims priority to European Patent Application No. 11180878.8, filed Sep. 12, 2011, the contents
HEYL as a therapeutic target and a diagnostic marker for neoplasia and uses therefor
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND OF THE INVENTION
Cancer causes one in every four US deaths and is the second leading cause of death among Americans. Among cancers, breast cancer represents the most common form of cancer among women. Each year, more than 180,000 and 1 million women in the U.S. and worldwide,
Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
This invention relates to compositions and methods for detecting and inhibiting cancer by targeting the expression, translation, and biological activity of liver-intestine cadherin (LI-cadherin), CDH17.
BACKGROUND OF THE INVENTION
Hepatocellular carcinoma (HCC), commonly
Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The present invention relates to the cancerology field. More particularly, the present invention relates to a method for diagnosing cancer, and more particularly breast, thyroid, lung or prostate cancer, in a human patient by in vitro determination of the presence of the nerve growth factor
Den mest komplette databasen med medisinske urter støttet av vitenskap
- Fungerer på 55 språk
- Urtekurer støttet av vitenskap
- Urtegjenkjenning etter bilde
- Interaktivt GPS-kart - merk urter på stedet (kommer snart)
- Les vitenskapelige publikasjoner relatert til søket ditt
- Søk medisinske urter etter deres effekter
- Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter
Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning
